Prostatype Genomics enters German market - Additional information
Prostatype Genomics can today announce its expansion in Germany, a key priority for the Company. Starting immediately, Karlheinz Dewald will represent the company and the Prostatype® prostate cancer test on the German market.
Karlheinz Dewald will represent Prostatype Genomics in the role of Director of Market development on the German market. Karlheinz has many years’ experience from commercial roles in leading enterprises in fields like biotechnology, oncology and urology. Most recent, Karlheinz led the implementation of new molecular biomarker in oncological diagnostic and treatment monitoring in Germany, Switzerland and Austria.
For Prostatype Genomics this is another important step into the German market. With Karlheinz proven record in business development and to establish sales force organizations, we are confident that we will see a rapid development.
Prostatype Genomics CEO, Fredrik Persson, comments:” I am very happy strengthening our German presence. This is a key milestone in Prostatype Genomics commercial plan, and we have been meticulous in finding the right person to further expand the use of Prostatype® in Germany. Karlheinz Dewald has the expertise and experience to represent innovative biomarkers, such as Prostatype®, in the diagnostic and prognostic field. Karlheinz also has an extensive network among urologists in Germany which will help us accessing key stakeholders.”Fredrik Persson
Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, firstname.lastname@example.org
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.